Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.34 USD | -0.14% | +8.97% | -4.97% |
Valuation
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Capitalization 1 | 534.4 | 423.7 | 503 | 455.3 | - | - |
Enterprise Value (EV) 1 | 243.3 | 378.5 | 503 | 351.8 | 314.1 | 295.5 |
P/E ratio | -2.1 x | -4.48 x | -75.5 x | -29.7 x | -3.79 x | -3.96 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | - | - | 3.9 x | 3.19 x | 13.5 x | 14 x |
EV / Revenue | - | - | 3.9 x | 2.47 x | 9.32 x | 9.06 x |
EV / EBITDA | -4.87 x | -3.97 x | -1,567 x | -12.4 x | -2.06 x | -1.81 x |
EV / FCF | - | - | - | - | - | - |
FCF Yield | - | - | - | - | - | - |
Price to Book | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 31,213 | 31,338 | 33,334 | 31,753 | - | - |
Reference price 2 | 17.12 | 13.52 | 15.09 | 14.34 | 14.34 | 14.34 |
Announcement Date | 3/15/22 | 3/6/23 | 3/13/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | 129 | 142.6 | 33.68 | 32.61 |
EBITDA 1 | - | -50.01 | -95.35 | -0.321 | -28.48 | -152.8 | -162.9 |
EBIT 1 | - | -51.13 | -97.25 | -3.162 | -20.16 | -145.7 | -150 |
Operating Margin | - | - | - | -2.45% | -14.13% | -432.58% | -459.94% |
Earnings before Tax (EBT) 1 | - | -51.16 | -94.62 | 12.06 | -7.234 | -144.9 | -160.3 |
Net income 1 | -26.52 | -51.16 | -94.62 | -6.685 | -17.69 | -146.8 | -162.9 |
Net margin | - | - | - | -5.18% | -12.4% | -435.92% | -499.67% |
EPS 2 | -3.320 | -8.160 | -3.020 | -0.2000 | -0.4833 | -3.788 | -3.617 |
Free Cash Flow | - | - | - | - | - | - | - |
FCF margin | - | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - |
Dividend per Share 2 | - | - | - | - | - | - | - |
Announcement Date | 8/6/21 | 3/15/22 | 3/6/23 | 3/13/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | 25.26 | 18.17 | 43.74 | 41.85 | 59.12 | 36.08 | 24.5 | 22.14 | - | - |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBIT 1 | -18.46 | -22.15 | -23.58 | -25.94 | -25.58 | -5.78 | -16.3 | 14.01 | 4.905 | 21.11 | -3.214 | -17.44 | -20.41 | - | - |
Operating Margin | - | - | - | - | - | -22.88% | -89.7% | 32.04% | 11.72% | 35.71% | -8.91% | -71.2% | -92.16% | - | - |
Earnings before Tax (EBT) 1 | -18.45 | -21.67 | -23.18 | -25.14 | -24.63 | -3.123 | -12.08 | 18.06 | 9.197 | 25.33 | -14 | -17.8 | -22.5 | - | - |
Net income 1 | -18.45 | -21.67 | -23.18 | -25.14 | -24.63 | -6.674 | -25.93 | 35.46 | -9.544 | 23.5 | -14 | -17.8 | -22.5 | - | - |
Net margin | - | - | - | - | - | -26.42% | -142.7% | 81.08% | -22.81% | 39.74% | -38.81% | -72.65% | -101.6% | - | - |
EPS 2 | -0.8900 | -0.6900 | -0.7400 | -0.8000 | -0.7800 | -0.2100 | -0.7800 | 1.020 | -0.2800 | 0.6800 | 0.1367 | -0.5200 | -0.5450 | -0.9650 | -1.005 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 3/15/22 | 5/12/22 | 8/11/22 | 11/7/22 | 3/6/23 | 5/10/23 | 8/8/23 | 11/7/23 | 3/13/24 | 5/7/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | - | - |
Net Cash position 1 | - | 291 | 45.2 | - | 104 | 141 | 160 |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - |
Capex 1 | - | - | 2.89 | - | 6.5 | 7 | 7.5 |
Capex / Sales | - | - | - | - | 4.56% | 20.78% | 23% |
Announcement Date | 8/6/21 | 3/15/22 | 3/6/23 | 3/13/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.97% | 455M | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- TRDA Stock
- Financials Entrada Therapeutics, Inc.